Post‐Transplant Circulating Tumor DNA and Recurrence Risk After Liver Transplantation for Hepatocellular Carcinoma
Clinical Transplantation · 2026-07 · 40 (7)
DOI: 10.1111/ctr.70615 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Transplantation, online erschienen am 09.07.2026. Verfasst von Sara Shahrestani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Sydney Medical School, University of Sydney, Sydney, Australia.
Zitieren
APA
Shahrestani, S., Karthik, M., Florman, S. S., Schwartz, M., & Tabrizian, P. (2026). Post‐Transplant Circulating Tumor DNA and Recurrence Risk After Liver Transplantation for Hepatocellular Carcinoma. Clinical Transplantation, 40(7). https://doi.org/10.1111/ctr.70615
Vancouver
Shahrestani S, Karthik M, Florman SS, Schwartz M, Tabrizian P. Post‐Transplant Circulating Tumor DNA and Recurrence Risk After Liver Transplantation for Hepatocellular Carcinoma. Clinical Transplantation. 2026;40(7). doi:10.1111/ctr.70615
BibTeX
@article{Shahrestani2026,
author = {Shahrestani, Sara and Karthik, Mukund and Florman, Sander S and Schwartz, Myron and Tabrizian, Parissa},
title = {Post‐Transplant Circulating Tumor DNA and Recurrence Risk After Liver Transplantation for Hepatocellular Carcinoma},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {7},
doi = {10.1111/ctr.70615}
}
EUVIMED